Lonza invests CHF 200 million in a new production facility in Visp

Biopharmaceutical company Lonza will build a new manufacturing facility dedicated to small molecules at its site in Visp. The new investment amounts to CHF 200 million and will create 200 new jobs.

Biopharma company Lonza has announced the construction of a new small molecule manufacturing complex at its site in Visp, in the canton of Valais.

This new facility will cover a total area of approximately 2,000 square meters, including six levels of manufacturing space. The complex will offer several opportunities for future expansion to support the supply of small molecule technologies, including pharmaceutical drugs.

The total investment comes to CHF 200 million and will lead to the creation of 200 new jobs.

The first stage of construction will be a production line dedicated to antibody-drug loading molecules (ADC), which are very useful in the treatment of certain cancers. The new infrastructure should be operational by the third quarter of 2023.

Lonza’s further expansion at its Visp site follows the construction in 2020 of new production lines for the manufacture of antibody-drug conjugates and a new building dedicated to the production of Moderna’s Covid-19 vaccine.

Founded in 1897 in the canton of Valais, Lonza is now active worldwide. The group employs around 14,000 people, including around 4,000 at its production site in Visp.